evidence/gaps
Cochrane · systematic review · CD010012

L‐acetylcarnitine for treating fragile X syndrome

Rueda, JR, Guillén, V, Ballesteros, J, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library

Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 83.3%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

L‐acetylcarnitine compared to placebo for treating fragile X syndrome

Population: people being treated for fragile X syndrome
6 questions
OutcomeEffectEvidenceStatus / GRADE
Outcomes: Behaviour or social performance
L‐acetylcarnitine vs placebo
no estimate extractedNRNo studies
Conners' Parent Rating Scale (raw scores)
L‐acetylcarnitine vs placebo
no estimate extracted1 study · 17 participantsLow
Downgraded: risk of bias
Conners' Parent Rating Scale (standardised t‐test scores)
L‐acetylcarnitine vs placebo
no estimate extracted1 study · 51 participantsLow
Downgraded: risk of bias
Conners' Teacher Rating Scale (standardised t‐test scores)
L‐acetylcarnitine vs placebo
no estimate extracted1 study · 51 participantsLow
Downgraded: risk of bias
Vineland Adaptive Behaviour Scale: adaptive behaviour composite (standardised scores)
L‐acetylcarnitine vs placebo
no estimate extracted1 study · 51 participantsLow
Downgraded: risk of bias
Vineland Adaptive Behaviour Scale: socialisation domain (standardised scores)
L‐acetylcarnitine vs placebo
no estimate extracted1 study · 51 participantsLow
Downgraded: risk of bias